Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups

Executive Summary

REPAIR will invest $20–40m per year over three–five years in 20 projects to combat antimicrobial resistance, with the hope that at least one of them will get to market.

Advertisement

Related Content

REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry
Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture
Alarm As Novartis Exits Antibiotics Space
Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal
New Report Calls For Pushing And Pulling In Global Fight Against Superbugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100478

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel